420 filings
Page 2 of 21
8-K
h6xnr5008l8sh65g
17 Oct 23
Amendments to Articles of Incorporation or Bylaws
4:02pm
8-K
x4nn5
3 Oct 23
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:05pm
8-K
o6m0f m2t6twy8ont
26 Sep 23
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
7:04am
8-K
sgp3te4k 92f23s
13 Sep 23
Entry into a Material Definitive Agreement
4:03pm
8-K
fdhzq2o75
13 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:12am
8-K
yycwjv5d6n
12 Sep 23
Avalo Enters into Agreement to Divest AVTX-800 Series
7:10am
8-K
8xl4jod 2nx7wnull52w
11 Sep 23
Other Events
7:22am
8-K
6o8nw0a
14 Aug 23
Entry into a Material Definitive Agreement
4:23pm
8-K
5ub ywbfw7xao245p7kr
8 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:11pm
8-K
ttxi9ffx1193bw78rqcp
7 Aug 23
Entry into a Material Definitive Agreement
5:27pm
424B5
ol0w7nepohe57
7 Aug 23
Prospectus supplement for primary offering
5:26pm
8-K
3p67 rlvlagtro
3 Aug 23
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:01am
8-K
is5qxk7nt7894
21 Jul 23
Entry into a Material Definitive Agreement
8:25am
8-K
d66fdqdqms5wvjjao
26 Jun 23
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
7:03am
8-K
6hsyj6dup j9pn
2 Jun 23
Entry into a Material Definitive Agreement
7:05am
S-8
5mvkb9b4p 25khue
4 May 23
Registration of securities for employees
5:10pm
424B5
th69v x0l
4 May 23
Prospectus supplement for primary offering
5:04pm
8-K
nxtua n9lcqrvo0xxle
4 May 23
Entry into a Material Definitive Agreement
4:56pm